Comment le bénéfice par action récent de LIMN se compare-t-il aux attentes ?
Comment les revenus de Liminatus Pharma Inc LIMN se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Liminatus Pharma Inc ?
Quel est le score de qualité des bénéfices pour Liminatus Pharma Inc ?
Quand Liminatus Pharma Inc publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Liminatus Pharma Inc ?
Liminatus Pharma Inc a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.4851
Prix d'ouverture
$0.4924
Plage de la journée
$0.3519 - $0.4995
Plage de 52 semaines
$0.3785 - $33.66
Volume
6.0M
Volume moyen
6.9M
BPA (TTM)
-0.20
Rendement en dividend
--
Capitalisation boursière
$10.2M
Qu’est-ce que LIMN ?
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.